Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Recruiting · NCT04765150 · Observational (researchers observe without assigning treatment) · Lead sponsor: Jonsson Comprehensive Cancer Center
View the official record on ClinicalTrials.gov →Interventions studied
3 Tesla Magnetic Resonance ImagingElectronic Health Record Review
What this trial is about
This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Male patients 18 years of age and older
- Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer
- Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)
- Ability to provide consent
Exclusion criteria
- Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)
- Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent
- Prior radiotherapy
Where it is running
1 location listed across 1 US state.
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles, California, United States